Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and ...(-Johnson Syndrome (SJS) andtoxic epiderm...),Health

Date:5/8/2008

-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

In late pregnancy, as with other NSAIDs, FLECTOR(R) Patch should be avoided because it may cause premature closure of the ductus arteriosus. Please see complete prescribing information for FLECTOR(R) Patch available at http://www.FlectorPatch.com.

Alpharma press releases are also available at our website: http://www.alpharma.com.

About Alpharma

Alpharma Inc. (NYSE: ALO) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 80 countries. Alpharma has a growing branded pharmaceutical franchise in the U.S. pain market with its KADIAN(R) (morphine sulfate extended-release) Capsules, and the FLECTOR(R) Patch (diclofenac epolamine topical patch) 1.3%. Alpharma is also internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.

Voltaren(R) is a registered trademark of a third party.

ALPHARMA(R) is a registered trademark of Alpharma Inc.

(C)2008 Alpharma Pharmaceuticals LLC. All rights reserved.

FLECTOR(R) is a registered trademark of Institut Biochimique SA.

(1) National Center for Health Statistics. Health, United States, 2006.

With Chartbook on Trends in the Health of Americans. Hyattsville, MD:

2006. (
'/>"/>

SOURCE Alpharma Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report